Current Edition

Functional Service Provision and Full Service Outsourcing Models Have Key Roles to Play in Outsourced Drug Development as Clinical Trials Evolve

The relative merits of the functional service provision (FSP) and full service (FS) outsourcing models have been debated repeatedly over at least the last ten years. There is a place for both in the outsourced market although, over time, there have been shifts between them in terms of market share. Andrew MacGarvey at PHASTAR analyses the pros and cons of the FS and FSP model, exploring whether hybrid is the compromise that will deliver the optimum outsourcing strategy.